184 related articles for article (PubMed ID: 31462295)
1. Telomere alterations in neurofibromatosis type 1-associated solid tumors.
Rodriguez FJ; Graham MK; Brosnan-Cashman JA; Barber JR; Davis C; Vizcaino MA; Palsgrove DN; Giannini C; Pekmezci M; Dahiya S; Gokden M; Noë M; Wood LD; Pratilas CA; Morris CD; Belzberg A; Blakeley J; Heaphy CM
Acta Neuropathol Commun; 2019 Aug; 7(1):139. PubMed ID: 31462295
[TBL] [Abstract][Full Text] [Related]
2. The molecular landscape of glioma in patients with Neurofibromatosis 1.
D'Angelo F; Ceccarelli M; Tala ; Garofano L; Zhang J; Frattini V; Caruso FP; Lewis G; Alfaro KD; Bauchet L; Berzero G; Cachia D; Cangiano M; Capelle L; de Groot J; DiMeco F; Ducray F; Farah W; Finocchiaro G; Goutagny S; Kamiya-Matsuoka C; Lavarino C; Loiseau H; Lorgis V; Marras CE; McCutcheon I; Nam DH; Ronchi S; Saletti V; Seizeur R; Slopis J; Suñol M; Vandenbos F; Varlet P; Vidaud D; Watts C; Tabar V; Reuss DE; Kim SK; Meyronet D; Mokhtari K; Salvador H; Bhat KP; Eoli M; Sanson M; Lasorella A; Iavarone A
Nat Med; 2019 Jan; 25(1):176-187. PubMed ID: 30531922
[TBL] [Abstract][Full Text] [Related]
3. Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.
Minasi S; Baldi C; Gianno F; Antonelli M; Buccoliero AM; Pietsch T; Massimino M; Buttarelli FR
Childs Nerv Syst; 2021 Mar; 37(3):809-818. PubMed ID: 33128602
[TBL] [Abstract][Full Text] [Related]
4. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
[TBL] [Abstract][Full Text] [Related]
5. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
[TBL] [Abstract][Full Text] [Related]
6. Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants.
Stundon JL; Ijaz H; Gaonkar KS; Kaufman RS; Jin R; Karras A; Vaksman Z; Kim J; Corbett RJ; Lueder MR; Miller DP; Guo Y; Santi M; Li M; Lopez G; Storm PB; Resnick AC; Waanders AJ; MacFarland SP; Stewart DR; Diskin SJ; Rokita JL; Cole KA
Neuro Oncol; 2023 Jul; 25(7):1331-1342. PubMed ID: 36541551
[TBL] [Abstract][Full Text] [Related]
7. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
8. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
Abedalthagafi M; Phillips JJ; Kim GE; Mueller S; Haas-Kogen DA; Marshall RE; Croul SE; Santi MR; Cheng J; Zhou S; Sullivan LM; Martinez-Lage M; Judkins AR; Perry A
Mod Pathol; 2013 Nov; 26(11):1425-32. PubMed ID: 23765250
[TBL] [Abstract][Full Text] [Related]
9. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
[TBL] [Abstract][Full Text] [Related]
10. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
11. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors.
Mangerel J; Price A; Castelo-Branco P; Brzezinski J; Buczkowicz P; Rakopoulos P; Merino D; Baskin B; Wasserman J; Mistry M; Barszczyk M; Picard D; Mack S; Remke M; Starkman H; Elizabeth C; Zhang C; Alon N; Lees J; Andrulis IL; Wunder JS; Jabado N; Johnston DL; Rutka JT; Dirks PB; Bouffet E; Taylor MD; Huang A; Malkin D; Hawkins C; Tabori U
Acta Neuropathol; 2014 Dec; 128(6):853-62. PubMed ID: 25315281
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Vulnerability to ATR Inhibition in Concurrent
Yuan M; Eberhart CG; Pratilas CA; Blakeley JO; Davis C; Stojanova M; Reilly K; Meeker AK; Heaphy CM; Rodriguez FJ
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740680
[TBL] [Abstract][Full Text] [Related]
13. Telomere length alterations and ATRX/DAXX loss in pituitary adenomas.
Heaphy CM; Bi WL; Coy S; Davis C; Gallia GL; Santagata S; Rodriguez FJ
Mod Pathol; 2020 Aug; 33(8):1475-1481. PubMed ID: 32203094
[TBL] [Abstract][Full Text] [Related]
14. Telomere erosion in NF1 tumorigenesis.
Jones RE; Grimstead JW; Sedani A; Baird D; Upadhyaya M
Oncotarget; 2017 Jun; 8(25):40132-40139. PubMed ID: 28454108
[TBL] [Abstract][Full Text] [Related]
15. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
[TBL] [Abstract][Full Text] [Related]
16. Frequent alternative lengthening of telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas.
Rodriguez FJ; Vizcaino MA; Blakeley J; Heaphy CM
Acta Neuropathol; 2016 Nov; 132(5):761-763. PubMed ID: 27650176
[No Abstract] [Full Text] [Related]
17. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
18. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance.
Venturini L; Daidone MG; Motta R; Cimino-Reale G; Hoare SF; Gronchi A; Folini M; Keith WN; Zaffaroni N
Neuro Oncol; 2012 Jun; 14(6):736-44. PubMed ID: 22516689
[TBL] [Abstract][Full Text] [Related]
19. Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs.
Miller DT; Cortés-Ciriano I; Pillay N; Hirbe AC; Snuderl M; Bui MM; Piculell K; Al-Ibraheemi A; Dickson BC; Hart J; Jones K; Jordan JT; Kim RH; Lindsay D; Nishida Y; Ullrich NJ; Wang X; Park PJ; Flanagan AM
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32252413
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic implications of NF1 gene alterations in diffuse gliomas.
Vizcaíno MA; Shah S; Eberhart CG; Rodriguez FJ
Hum Pathol; 2015 Sep; 46(9):1323-30. PubMed ID: 26190195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]